The FDA’s January 2026 announcement on “Flexible Requirements for Cell and Gene Therapies” has sent ripples through the industry. While the headlines promise “advanced innovation,” the operational reality is far more complex. In our latest podcast episode, the DES Pharma team breaks down why this newfound regulatory flexibility might actually be an operational straitjacket if not managed correctly.
The “Phase 2/3 Exemption”: Fact vs. Friction
The FDA officially codified that manufacturers of certain cell and gene therapies (CGTs) do not need to strictly comply with 21 CFR Part 211 (current GMP for finished pharmaceuticals) before Phase 2 or 3.
While this sounds like a shortcut, we are concerned that it is a double-edged sword. By using a single, large GMP batch to service an entire clinical program, you effectively “lock” your process earlier than ever. Without the data from multiple clinical runs, you lose the ability to statistically justify wider specifications.
The “End-of-One” Trap: If your first clinical batch has a host cell protein level of 17 ng/mL, that may become your de facto commercial limit. If your later scale-up hits 25 ng/mL—even if it’s safe—you could fail your Process Performance Qualification (PPQ) because you lack the historical data to prove that range is acceptable.
The 3-Lot Rule is Dead (For Some)
The FDA has explicitly stated that three PPQ lots are no longer a hard requirement. However, this isn’t a “get out of jail free” card. This flexibility is primarily aimed at ultra-rare indications where producing three lots would exceed the total patient need. For broader indications, the agency still expects a science-based justification for your lot count, often shifting the remaining validation work into Continuous Process Validation (CPV) post-licensure.
Supply Chain: The “Pull-Forward” Strategy
From a procurement perspective, we highlight that this “flexibility” requires a massive shift in mindset. Because you are moving from Phase 1 almost directly to commercialization, you must:
-
-
Engage commercial teams early: Your Phase 1 CDMO must be capable of commercial supply.
-
Lock raw material specs: There is no room for “minor changes” if you haven’t performed the risk assessments upfront.
-
Audit rigorously: Supplier qualification must be “commercial-ready” from day one.
-
The overarching message from our team? Minimize change. To take advantage of these flexibilities, your process, analytics, and raw materials must stay as static as possible.
Senior Consultant, Process Development & CMC
